Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/605—Glucagons

Definitions

• the at least one therapeutically effective amount of apraglutide can be administered to the subject prior to the subject being administered a transplant.
• the at least one therapeutically effective amount of apraglutide can be administered to the subj ect after the subj ect has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof.
• FIG. 6 is a series of graphs showing that apraglutide protects against chemotherapy- induced damage to small intestine.
• the subject has been previously diagnosed with GvHD and the GvHD is ongoing at the time of the administration of apraglutide. In some aspects, the subject has been previously diagnosed with GvHD and the GvHD has been successfully treated prior to the administration of apraglutide.
• the subject weighs more than 50 kg. In some aspects, the subject weighs between 50 kg and 40 kg. In some aspects, the subject weighs less than 40 kg.
• the present disclosure provides apraglutide, or a pharmaceutically acceptable salt thereof, for use in treating GvHD-induced intestinal damage in a subject, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is for administration to the subject in at least one therapeutically effective amount.
• the present disclosure provides apraglutide, or a pharmaceutically acceptable salt thereof, for use in treating GvHD-induced intestinal damage in a subject.
• the subject has been previously diagnosed with GvHD and the GvHD is ongoing at the time of the administration of apraglutide. In some aspects, the subject has been previously diagnosed with GvHD and the GvHD has been successfully treated prior to the administration of apraglutide.
• chronic GvHD can be chronic gastrointestinal GvHD.
• the GvHD can be steroid-refractory chronic gastrointestinal GvHD.
• the GvHD can be steroid-naive chronic gastrointestinal GvHD.
• a subject can be diagnosed with a disease or disorder.
• the disease or disorder can be at least one of a hemoglobinopathy, a congenital hemoglobinopathy, P-Thalessemia major (TM), sickle cell disease (SCD), severe aplastic anemia, Fanconi's anemia, dyskeratosis congenita, Blackfan- Diamond anemia, Thalassemia, congenital amegakaryocytic thrombocytopenia, severe combined immunodeficiency, T cell immunodeficiency, T cell immunodeficiency-SCID variants, Wiskott- Aldrich syndrome, a hemophagocytic disorder, a lymphoproliferative disorder, severe congenital neutropenia, chronic granulomatous disease, a phagocytic cell disorder, IPEX syndrome, juvenile rheumatoid arthritis, systemic sclerosis, an autoimmune disorder, an immune dysregulation disorder,
• TM P-Thalessemia major
• SCD sickle cell disease
• a subject can be diagnosed with a disease or disorder.
• the disease or disorder may be at least one of a hemoglobinopathy, a congenital hemoglobinopathy, P-Thalessemia major (TM), sickle cell disease (SCD), severe aplastic anemia, Fanconi's anemia, dyskeratosis congenita, Blackfan-Diamond anemia, Thalassemia, congenital amegakaryocytic thrombocytopenia, severe combined immunodeficiency, T cell immunodeficiency, T cell immunodeficiency-SCID variants, Wiskott-Aldrich syndrome, a hemophagocytic disorder, a lymphoproliferative disorder, severe congenital neutropenia, chronic granulomatous disease, a phagocytic cell disorder, IPEX syndrome, juvenile rheumatoid arthritis, systemic sclerosis, an autoimmune disorder, an immune dysregulation disorder, mucopolysaccharoidoses,
• a subject can be diagnosed with a cancer and be designated to undergo an autologous transplant in order to treat the cancer. In some aspects, of the methods and uses of the present disclosure, a subject can be diagnosed with a cancer and has previously undergone an autologous transplant in order to treat the cancer.
• a subject can be diagnosed with a disease or disorder and be designated to undergo an allogeneic transplant in order to treat the disease or disorder. In some aspects, of the methods and uses of the present disclosure, a subject can be diagnosed with a disease or disorder and has previously undergone an allogeneic transplant in order to treat the disease or disorder.
• a subject can have been previously administered a transplant. Accordingly, apraglutide, or a pharmaceutically acceptable salt thereof, can be administered to the subject after the latter has been administered a transplant.
• a subject can have been previously administered a conditioning therapy in connection with a transplant.
• a subject can have been previously administered a conditioning therapy in connection with an allogeneic transplant.
• a subject can have been previously administered a conditioning therapy in connection with an autologous transplant.
• a conditioning therapy can comprise the administration of radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof.
• a radiation therapy can comprise total body irradiation.
• apraglutide can be administered to a subject prior to the subject being administered a solid organ transplant. In some aspects, of the methods and uses of the present disclosure, apraglutide can be administered prior the subject being administered radiation therapy, chemotherapy, or radiomimetic therapy in connection with the solid organ transplant. In some aspects, of the methods and uses of the present disclosure, apraglutide is administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof and prior to the subject being administered a solid organ transplant.
• apraglutide can be administered to a subject prior to the subject being administered an allogeneic transplant. In some aspects, of the methods and uses of the present disclosure, apraglutide can be administered prior the subject being administered radiation therapy, chemotherapy, or radiomimetic therapy in connection with the allogeneic transplant. In some aspects, of the methods and uses of the present disclosure, apraglutide is administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof and prior to the subject being administered an allogeneic transplant.
• an at least one therapeutically effective amount of apraglutide can be administered to a subject prior to the subject being administered an autologous transplant. In some aspects, of the methods and uses of the present disclosure, an at least one therapeutically effective amount of apraglutide can be administered prior the subject being administered radiation therapy, chemotherapy, or radiomimetic therapy in connection with the autologous transplant. In some aspects, of the methods and uses of the present disclosure, an at least one therapeutically effective amount of apraglutide is administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof and prior to the subject being administered an autologous transplant.
• apraglutide, or a pharmaceutically acceptable salt thereof can be administered to the subject concurrently with a transplant.
• apraglutide, or a pharmaceutically acceptable salt thereof can be administered to the subject concurrently with an allogeneic transplant.
• apraglutide, or a pharmaceutically acceptable salt thereof can be administered to the subject concurrently with an autologous transplant.
• an at least one therapeutically effective amount of apraglutide can be administered to a subject concurrently with a conditioning therapy.
• an at least one therapeutically effective amount of apraglutide least one therapeutically effective amount of apraglutide can be administered to a subject concurrently with a radiation therapy, a chemotherapy, a radiomimetic therapy, or any combination thereof.
• apraglutide, or a pharmaceutically acceptable salt thereof can be administered to the subject concurrently with a conditioning therapy, such as a conditioning therapy as defined above.
• administration of apraglutide can prevent and/or attenuate a reduction in colon length in a subject following an allogeneic transplant.
• administration of apraglutide prevents and/or attenuates a reduction in colon length in a subject following a conditioning therapy and a transplant.
• administration of apraglutide prevents and/or attenuates a reduction in colon length in a subject following a conditioning therapy and an allogeneic transplant.
• administration of apraglutide prevents and/or attenuates a reduction in colon length in a subject following a conditioning therapy and an autologous transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) a therapeutically effective amount of apraglutide; and b) a transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) a therapeutically effective amount of a conditioning therapy; b) a therapeutically effective amount of apraglutide; and c) a transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) a therapeutically effective amount of a radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof; b) a therapeutically effective amount of apraglutide; and c) a transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) apraglutide; and b) a transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) a conditioning therapy; b) apraglutide; and c) a transplant.
• the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject: a) radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof; b) apraglutide; and c) a transplant.
• the present disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject: a) a therapeutically effective amount of a radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof; b) a therapeutically effective amount of apraglutide; and c) an allogeneic transplant.
• the present disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject: a) apraglutide; and b) an allogeneic transplant.
• the present disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject: a) conditioning therapy; b) apraglutide; and c) an allogeneic transplant.
• the present disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject: a) radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof; b) apraglutide; and c) an allogeneic transplant.
• the present disclosure provides a method of treating a disease or disorder in a subject, the method comprising administering to the subject: a) a therapeutically effective amount of a radiation therapy, chemotherapy, radiomimetic therapy or any combination thereof; b) a therapeutically effective amount of apraglutide; and c) an autologous transplant.
• an autologous transplant can comprise autologous hematopoietic stem cells.
• the autologous hematopoietic stem cells can be derived from bone marrow, peripheral blood, umbilical cord blood or any combination thereof.
• a transplant can comprise T-cells.
• T-cells can be chimeric antigen receptor (CAR) T-cells.
• an allogeneic transplant can comprise allogeneic T-cells.
• allogeneic T-cells can be allogenic chimeric antigen receptor (CAR) T-cells.
• an autologous transplant can comprise autologous T-cells.
• autologous T-cells can be autologous chimeric antigen receptor (CAR) T-cells.
• apraglutide can be part of a pharmaceutical composition.
• Pharmaceutical compositions can further comprise any pharmaceutically acceptable carrier and/or excipient.
• pharmaceutically acceptable carriers and/or excipients include mannitol, glycine, L-histidine or any combination thereof.
• steroid-refractory refers to GvHD that has been previously treated using steroid therapy, but has become non-responsive to the steroid therapy.
• steroid-refractory acute gastrointestinal GvHD refers to acute gastrointestinal GvHD that has been previous treated using a steroid therpay, but has become non-responsive to steroid therapy.
• subjects with steroid-refractory GvHD are administered a pharmaceutical composition comprising ruxolitinib.
• GI-aGVHD response refers to a decrease of one stage in the signs and symptoms of GI-aGVHD without any intercurrent events of discontinuation of the assigned apraglutide treatment, institution of new systemic therapy, or death.
• a complete GI-aGVHD response refers to the resolution of all GI-aGVHD signs and symptoms GVHD without any intercurrent events of discontinuation of the assigned apraglutide treatment, institution of new systemic therapy, or death.
• autologous refers to biological material isolated from a donor that is to be transplanted into a recipient, wherein the donor and the recipient is the same subject.
• conditioning therapy refers to the use of radiation therapy, such as total body irradiation, chemotherapy, or radiomimetic therapy that typically administered to a subject prior to an HSCT.
• radiation therapy such as total body irradiation, chemotherapy, or radiomimetic therapy that typically administered to a subject prior to an HSCT.
• the aims of conditioning therapy include: a) eradication of the underlying disease (e.g. cancer, a blood cancer) that is to be treated using by the HSCT; b) creation of space in the bone marrow for donor stem cells to engraft; and c) immunosuppression to decrease the risk of rejection of the donor cells by the host cells.
• conditioning therapy can refer to any conditioning therapy known in the art, including, but not limited to, total body irradiation.
• radiomimetic therapy refers to any drug, compound or treatment known in the art that imitates the effects of radiation.
• chemotherapy includes the administration of a therapeutically effective amount of at least one chemotherapeutic agent.
• references to “treating” or “treatment” include the alleviation of established symptoms of a condition.
• “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
• administer refers to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like. Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics, current ed.; Pergam on; and Remington’s, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
• apraglutide can be co-administered with other therapeutic agents.
• co-administration are meant to encompass administration of two or more therapeutic agents to a single subject, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different times.
• apraglutide will be co-administered with other agents. These terms encompass administration of two or more agents to the subject so that both agents and/or their metabolites are present in the subject at the same time.
• subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount from about 3.75 mg to about 7.5 mg. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount from about 4 mg to about 7.5 mg. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 3.75 mg. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 4 mg. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 7.5 mg.
• subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount from about 3.75 mg to about 7.5 mg per week. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount from about 4 mg to about 7.5 mg per week. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 3.75 mg. In In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 4 mg per week. In some aspects, subjects with a body weight of 60 kg to 80 kg can be administered apraglutide in an amount of about 7.5 mg per week.
• subjects with a body weight of 80 kg or great can be administered apraglutide in an amount from about 5 mg to about 10 mg. In some aspects, subjects with a body weight of 80 kg or great can be administered apraglutide in an amount of about 5 mg. In some aspects, subj ects with a body weight of 80 kg or great can be administered apraglutide in an amount of about 10 mg.
• the compounds or the corresponding pharmaceutical compositions taught herein can be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
• the compounds of the present teachings may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and the pharmaceutical compositions formulated accordingly.
• Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration can be by continuous infusion over a selected period of time.
• the pharmaceutical composition of the application is formulated to be compatible with its intended route of administration.
• the composition may be formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings.
• the pharmaceutical composition is formulated for intravenous administration.
• the oral therapeutic administration may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• Apraglutide can be administered as part of a pharmaceutical composition.
• Pharmaceutical compositions of apraglutide can comprise any pharmaceutically acceptable carrier and/or excipient.
• Pharmaceutical compositions of apraglutide can comprise glycine, L-histidine, mannitol, and any combination thereof.
• Ovarian cancer Pancreatic cancer, Penile cancer, Persistent trophoblastic disease and choriocarcinoma, Pheochromocytoma, Prostate cancer. Pseudomyxoma peritonei, Rectal cancer. Retinoblastoma, Salivary gland cancer, Secondary'' cancer, Signet cell cancer, Skin cancer, Small bowel cancer, Soft tissue sarcoma, Stomach cancer, T cell childhood non Hodgkin lymphoma (NHL), Testicular cancer, Thymus gland cancer, Thyroid cancer, Tongue cancer, Tonsil cancer, Tumors of the adrenal gland, Uterine cancer.
• NHL Hodgkin lymphoma
• the cancer is a hematological cancer.
• a disease or disorder is a hemoglobinopathy, a congenital hemoglobinopathy, P-Thalessemia major (TM), sickle cell disease (SCD), severe aplastic anemia, Fanconi's anemia, dyskeratosis congenita, Blackfan-Diamond anemia, Thalassemia, congenital amegakaryocytic thrombocytopenia, severe combined immunodeficiency, T cell immunodeficiency, T cell immunodeficiency-SCID variants, Wiskott-Aldrich syndrome, a hemophagocytic disorder, a lymphoproliferative disorder, severe congenital neutropenia, chronic granulomatous disease, a phagocytic cell disorder, IPEX syndrome, juvenile rheumatoid arthritis, systemic sclerosis, an autoimmune disorder, an immune dysregulation disorder, mucopolysaccharoidoses, MPS-I, MPS-VI, osteopetrosis, a
• the term “temporal proximity” refers to that administration of one therapeutic composition (e.g., apraglutide, or a pharmaceutically acceptable salt thereof) occurs within a time period before or after the administration of another therapeutic composition (e.g., a transplant, a conditioning therapy, a second active agent), such that the therapeutic effect of the one therapeutic agent overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, the therapeutic effect of the one therapeutic agent completely overlaps with the therapeutic effect of the other therapeutic agent. In some embodiments, “temporal proximity” means that administration of one therapeutic agent occurs within a time period before or after the administration of another therapeutic agent, such that there is a synergistic effect between the one therapeutic agent and the other therapeutic agent.
• one therapeutic composition e.g., apraglutide, or a pharmaceutically acceptable salt thereof
• “temporal proximity” means within 15 minutes, within 30 minutes, within an hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within a week, within 2 weeks, within 3 weeks, within 4 weeks, with 6 weeks, or within 8 weeks.
• multiple administration of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent.
• temporal proximity may change during a treatment cycle or within a dosing regimen.
• Embodiment 6 The method of any one of embodiments 1-4, wherein the GvHD is steroidnaive.
• Embodiment 7 The method of any one of the preceding embodiments, wherein the at least one therapeutically effective amount of apraglutide is administered to the subject prior to the subject being administered a transplant.
• Embodiment 9 The method of any one of embodiments 1-6, wherein the subject has been previously administered a transplant.
• Embodiment 10 The method of embodiment 9, wherein the at least one therapeutically effective amount of apraglutide is administered to the subject after the subject has been administered a transplant.
• Embodiment 12 The method of embodiment 11, wherein the at least one therapeutically effective amount of apraglutide is administered to the subject after the subject has been administered radiation therapy, chemotherapy radiomimetic therapy or any combination thereof.
• Embodiment 18 The method of any one of the preceding embodiments, wherein the transplant comprises hematopoietic stem cells derived from bone marrow, peripheral blood, umbilical cord blood or any combination thereof.
• Embodiment 23 The method of any one of the preceding embodiments, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is administered by subcutaneous injection.
• Embodiment 24 The method of any one of the preceding embodiments, wherein the apraglutide, or pharmaceutically acceptable salt thereof, is administered in an amount of between about 1 mg to about 10 mg.
• Embodiment 25 The method of any one of the preceding embodiments, wherein the apraglutide is administered in an amount of about 2.5 mg.
• Embodiment 31 The method of embodiment 30, wherein the at least one anti-GvHD therapy comprises steroid therapy.
• Embodiment 42 Apraglutide, or a pharmaceutically acceptable salt thereof, for use according to any one of embodiments 32-36 in a subject designed to be concurrently administered an allogeneic transplant.
• Embodiment 50 Apraglutide, or a pharmaceutically acceptable salt thereof, for use according to any one of the preceding embodiments, wherein the pharmaceutically acceptable salt of apraglutide is the sodium salt of apraglutide.
• Embodiment 54 Apraglutide, or a pharmaceutically acceptable salt thereof, for use according to any one of the preceding embodiments, wherein the apraglutide is administered in an amount of about 5 mg.
• Embodiment 55 Apraglutide, or a pharmaceutically acceptable salt thereof, for use according to any one of the preceding embodiments, wherein the apraglutide is administered in an amount of about 10 mg.
• Example 1 In a first experiment BALB/cJ male mice were separated into two groups, Group A and Group B. Each group consisted of 10 mice.
• mice in Group A received subcutaneous injections of apraglutide in an amount of 3 mg/kg/mouse (administered in 300 pl of vehicle), every second day from Day -9 to Day +7 (Days: -9, -7, -5, -3 -1, +1, +3, +5, +7).
• mice in Group B received subcutaneous injections of 300 pl of vehicle control every second day starting from Day -9 to Day +7 (Days: -9, -7, -5, -3 -1, +1, +3, +5, +7).
• mice Following sacrifice of the mice, the colon lengths of the mice in Group A and Group B, as well as a control group of BALB/c mice (untreated), were measured. The results of this analysis are shown in FIG. 1. As shown in FIG. 1, there was a clear difference in colon lengths in Group A as compared to Group B, as the mice that were treated with apraglutide showed increased colon lengths that were nearly the same as the control mice. Thus, treatment with apraglutide protected the mice in Group A from a reduction in colon length, which is typically attributed to the inflammation caused by acute, gastrointestinal GvHD.
• mice treated with apraglutide the overall mean severity score of mucosal degenerative/inflammatory changes (shortening of villi [villous atrophy], mononuclear [lymphohistiocytic] /neutrophilic cell infiltrate in the lamina intestinal/intra-cryptal epithelium, decreased number of crypts and cryptal abscess) was slightly decreased in the jejunum, when compared with the animals treated with vehicle. Additionally, the mean severity score of the regenerative cryptal hyperplasia was slightly increased, when compared with the animals treated with vehicle. These indicate that the administration of apraglutide has a protective effective against jejunal mucosal damages induced by irradiation and GvHD.
• mice in Group B received subcutaneous injections of 300 pl of vehicle control every second day starting from Day -9 to Day +7 (Days: -9, -7, -5, -3 -1, +1, +3, +5, +7).
• mice in Group C received subcutaneous injections of 300 pl of vehicle control every second day starting from Day -9 to Day +7 (Days: -9, -7, -5, -3 -1, +1, +3, +5, +7).
• mice in Groups A and B were irradiated with 7.0 Gy using an linac x-ray source.
• Group C was not irradiated but were injected with the vehicle only.
• mice in Group A that were treated with apraglutide exhibited enhanced survival as compared to the irradiate, untreated mice in Group B.
• Group A had a median survival of 9 days and Group B had a median survival of 8.5 days.
• 40% of apraglutide treated mice survived past Day 9 of the experiment.
• Group C mice received only the vehicle and were expected to survive.
• FIG. 14 [00293] Morbidity, mortality, body weight, clinical signs (diarrhea, appearance and behavior), length of intestinal segments, and histopathology of the intestine, skin, spleen and liver were monitored in the mice of Group A, Group B and Group C. All mice were sacrificed at Day +14 at the latest.
• TBI-induced intestinal damaged BALB/cJ mice received allogeneic transplantation and were treated with apraglutide (3.3 mg/kg) or vehicle on Days -9, - 7, -5, -3 -1, +1, +3, +5, +7.
• Intestinal damage indicative of GvHD histological changes, length, hemorrhage, inflammation), body weight, and survival were assessed.
• apraglutide’ s effect on the ability of cytarabine to induce immunosuppression was assessed.
• the experiment included three groups of Balb/c mice: (A) vehicle; (B) cytarabine on Days 5-9; (C) cytarabine on Days 5-9, concomitant apraglutide on Days 5-18.
• RBC, platelets, WBC, NEU and LYMPH were assessed.
• a cohort was allowed to survive for 4 weeks to assess the effect of apraglutide on immunosuppression recovery (FIG. 12).
• Participants have histologically diagnosed GI-aGVHD at screening (with clinically confirmed SR GI-aGVHD at ruxolitinib start and prior to apraglutide start) defined as subjects administered SS, given alone or combined with calcineurin inhibitors (CNI) and either: a) Disease progression based on organ assessment after 3 days of systemic methylprednisolone (MP) of 2mg/kg +/- CNI; or b) Did not improve after 7 days of treatment with MP 2mg/kg/day equivalent; or c) Progressed to a new organ after treatment with MP 2 mg/kg/day equivalent for skin and upper GI-aGVHD; or d) Recurred during or after a steroid taper. All subjects must have Stage 1-4 lower GI-aGVHD at enrollment.
• CNI calcineurin inhibitors

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Cell Biology (AREA)
• Endocrinology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Virology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Developmental Biology & Embryology (AREA)
• Hematology (AREA)
• Transplantation (AREA)
• Toxicology (AREA)
• Dermatology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (12)

Applications Claiming Priority (4)

Publications (1)

Family

ID=80461100

Family Applications (1)

Country Status (11)

Families Citing this family (1)

Citations (3)

Family Cites Families (1)

• 2022
  • 2022-01-28 CA CA3206093A patent/CA3206093A1/en active Pending
  • 2022-01-28 WO PCT/US2022/014349 patent/WO2022165204A1/en not_active Ceased
  • 2022-01-28 ES ES22705498T patent/ES3044110T3/es active Active
  • 2022-01-28 EP EP25186217.3A patent/EP4635509A1/en active Pending
  • 2022-01-28 US US17/587,311 patent/US20220233645A1/en not_active Abandoned
  • 2022-01-28 EP EP22705498.8A patent/EP4284410B1/en active Active
  • 2022-01-28 MX MX2023008793A patent/MX2023008793A/es unknown
  • 2022-01-28 KR KR1020237029222A patent/KR20230167019A/ko active Pending
  • 2022-01-28 BR BR112023014978A patent/BR112023014978A2/pt unknown
  • 2022-01-28 US US18/274,622 patent/US20240123036A1/en active Pending
  • 2022-01-28 AU AU2022212119A patent/AU2022212119A1/en active Pending
  • 2022-01-28 JP JP2023544229A patent/JP2024507324A/ja active Pending
• 2023
  • 2023-07-24 IL IL304675A patent/IL304675A/en unknown
  • 2023-10-13 US US18/486,390 patent/US20240285730A1/en not_active Abandoned

Patent Citations (5)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events